PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ:TXG), a company specialized in single cell and spatial biology, announced the commencement of shipments for two new products incorporating its GEM-X technology.
The products, named Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, are designed to deliver improved performance and cost efficiency in single-cell analysis.
The GEM-X technology, exclusively compatible with the Chromium X Series instruments, is described as a leap forward in single-cell technology architecture. It incorporates a novel microfluidic chip design and optimized reagents to enhance research capabilities.
The benefits outlined include doubled gene detection sensitivity, a two-fold increase in cells captured per channel, and a reduction in cost per cell by more than half. Furthermore, data quality is bolstered with a two-fold decrease in multiplet rate, and sample recovery rates have improved to up to 80%.
Researchers anticipate that the increased transcript capture capacity of GEM-X will aid in distinguishing cell types, identifying rare cells, and decoding regulatory pathways with greater accuracy.
Luciano Martelotto, an Associate Professor at the University of Adelaide, highlighted the importance of identifying more genes per cell to enrich the understanding of cellular functions and biological intricacies.
10x Genomics positions itself as a life science technology company aiming to advance human health by providing integrated solutions in single cell and spatial biology. Their products are used in various fields including oncology, immunology, and neuroscience, contributing to significant scientific discoveries.
The company's forward-looking statements indicate plans for further product launches and advancements in their pipeline, although these are subject to a number of factors and uncertainties that could affect the actual outcomes and results. This press release is based on information available as of its date and is used by 10x Genomics for compliance with their disclosure obligations.
The announcement of these shipments marks an important milestone for 10x Genomics in its efforts to make single-cell analysis more accessible to the broader scientific community. This news is based on a press release statement from 10x Genomics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.